Impact of Efavirenz on Hormone-Positive Breast Cancer Survival in Women Living With HIV

Authors

Arthur T Johnson
Taolo Ntloedibe
Jose Euberto Mendez Reyes
Mogomotsi S Matshaba
Scott L Dryden-Peterson
Elizabeth Y Chiao

Publication Date

7-15-2024

Journal

AIDS

DOI

10.1097/QAD.0000000000003912

PMID

38932749

PMCID

PMC11212673

PubMedCentral® Posted Date

6-27-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

Humans, Benzoxazines, Cyclopropanes, Female, Alkynes, Breast Neoplasms, HIV Infections, Middle Aged, Adult, Anti-HIV Agents, Survival Analysis, Aged

Abstract

Women living with HIV and breast cancer have poorer survival than HIV-negative women. Efavirenz-estrogen interactions are documented; however, the survival impact is unknown. Survival between women with estrogen-receptor positive breast cancer taking efavirenz (n = 38) and nonefavirenz regimens (n = 51) were compared. The 5-year overall-survival was 48.9% [95% confidence interval (CI) 33.0-72.2 and 51.1% (95% CI 34.0-76.8)] in the efavirenz and nonefavirenz groups, respectively suggesting efavirenz is unlikely driving poorer survival in women living with HIV and estrogen-receptor positive breast cancer.